Arcus Biosciences to Present at the 2019 Cantor Global Healthcare Conference
A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has four programs in the clinic targeting important oncology/immuno-oncology pathways: (1) AB928, a dual adenosine receptor antagonist (A2a and A2b receptors), being evaluated in several Phase 1/1b trials in combination with multiple regimens across a range of tumor types, (2) AB680, a small molecule inhibitor of CD73 progressing into a Phase 1/1b pancreatic cancer trial, (3) AB122, an anti-PD-1 antibody progressing into a biomarker-selected tumor-agnostic Phase 1b trial, and (4) AB154, an anti-TIGIT antibody being evaluated in combination with AB122. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Utilizing these unique capabilities, Arcus has created a world-class drug discovery organization focused on the development of a growing portfolio of innovative therapies for the treatment of cancer. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005858/en/
Source: Arcus Biosciences